The CMS released draft 2027 Medicare Advantage (MA) star rating thresholds this week, and the grading sheet just got tougher. About 50% of cutpoints — the benchmarks used to convert plan performance into a 1–5 star score — got harder to reach, 33% stayed the same, and only 17% got easier, per analysis by the Newton Smith Group. The tightening is largely driven by HEDIS measures, as plans invest more in data collection and raise the bar for peers industry-wide.

The stakes couldn't be higher. Star ratings are directly tied to bonus payments, and even a half-star change can mean hundreds of millions of dollars for a plan. UnitedHealthcare, the largest MA insurer, looks most at risk — analysts project its raw scores could drop across 9 of its 10 largest contracts if performance hasn't improved. Humana, meanwhile, is expected to hold roughly steady, and has signaled its stars will be "meaningfully higher" in 2027 after a difficult two-year slide.

By the Numbers:

• ~50% of cutpoints got harder to reach for 2027
• Kidney Health Evaluation for Patients with Diabetes thresholds rose by 7–10 points
• Colorectal Cancer Screening thresholds tightened by 4–11 points
• CMS paid out at least $12.7B in MA bonus payments last year
• The federal government is estimated to overpay $76B for MA seniors vs. traditional Medicare in 2026
• 35M+ people are enrolled in MA — more than half of all eligible Medicare beneficiaries

Why it matters: With billions in bonuses at stake and a contested legal methodology still in play, the 2027 star ratings cycle could trigger another wave of insurer lawsuits — further destabilizing a program already under scrutiny for complexity, shifting goalposts, and questions about whether it actually improves care quality.